AXGN Stock: Price, Earnings History and SEC Filings
Axogen, Inc. (AXGN) last traded at $49.37, down 0.52% on the latest session and up 17.8% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.04 against an analyst estimate of $-0.03, a beat of 233.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
AXGN earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 28, 2026 | $0.04 | $-0.03 | +233.33% |
| Jun 2026 | Jul 29, 2026 | $-0.03 | $-0.04 | +25.00% |
| Mar 2026 | Apr 28, 2026 | $-0.05 | $-0.28 | +82.14% |
| Dec 2025 | Feb 24, 2026 | $-0.28 | $-0.01 | -2700.00% |
AXGN beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How AXGN reacts to earnings
Across its last 8 earnings releases, AXGN moved 13.5% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-28 | Before open | +31.47% |
| 2026-07-29 | Before open | +0.53% |
| 2026-04-28 | Before open | +6.60% |
| 2026-02-24 | Before open | -8.14% |
| 2026-01-12 | Before open | -5.85% |
| 2025-10-29 | Before open | +23.06% |
| 2025-08-05 | Before open | +9.32% |
| 2025-05-08 | Before open | -23.18% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
AXGN financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $225M | -$16M | -$3M | -7.0% | $-0.34 |
| 2024 | $187M | -$10M | $1M | -5.3% | $-0.23 |
| 2023 | $159M | -$22M | -$20M | -13.7% | $-0.51 |
| 2022 | $139M | -$29M | -$36M | -20.9% | $-0.69 |
| 2021 | $127M | -$27M | -$41M | -21.2% | $-0.65 |
| 2020 | $112M | -$24M | -$32M | -21.2% | $-0.60 |
| 2019 | $107M | -$29M | -$25M | -27.3% | $-0.74 |
| 2018 | $84M | -$22M | -$24M | -26.7% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for AXGN
- 10-Q · Oct 28, 2026
- 8-K · Oct 28, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Oct 1, 2026Regulation FD disclosure, Financial statements and exhibits
- 424B5 · Sep 10, 2026
- 8-K · Sep 10, 2026Material agreement, Regulation FD disclosure, Other events
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Jun 23, 2026Shareholder vote
- DEF 14A · Apr 29, 2026
- 10-Q · Apr 28, 2026
Insider filing activity
AXGN insiders filed 4 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
AXGN news
- GeneDx Holdings And 2 Other Top Healthcare StocksOct 31, 2026 · finance.yahoo.com
- Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?Oct 29, 2026 · finance.yahoo.com
- Does Axogen (AXGN) Have More Upside Or Is It Fully Priced?Oct 28, 2026 · finance.yahoo.com
- AxoGen Q3 Earnings Call HighlightsOct 28, 2026 · marketbeat.com
- AxoGen, Inc. Q3 2026 Earnings Call SummaryOct 28, 2026 · app.moby.co
- AxoGen: Q3 Earnings SnapshotOct 28, 2026 · finance.yahoo.com
- Axogen (AXGN) Q3 2026 Earnings Call TranscriptOct 28, 2026 · fool.com
- AxoGen (AXGN) Beats Q3 Earnings and Revenue EstimatesOct 28, 2026 · finance.yahoo.com
About Axogen, Inc.
Axogen, Inc. (AXGN) is a US-listed public company on Nasdaq. The SEC classifies its business as Electromedical & Electrotherapeutic Apparatus. It is incorporated in MN. Its fiscal year ends in December.